Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeAdvanced

Right of First Negotiation With SUSMED,Inc. for a PMS/PMDD Treatment App

First written in FY2023-Q1. 3 of 4 entries say "Advanced", first in FY2024-Q2. Latest entry: 2026-08-04.

4entries
5years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q1AdvancedFY2024-Q2 – 2026-08-042022: 120222023: 120232024: 020242025: 020252026: 22026
Same theme, other companies
Joint Development and Exclusive Sales Partnership with SUSMED for a PMS and PMDD Treatment AppA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Moved together

"Clinical Development of AKP-009 for Benign Prostatic Hyperplasia" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22★12
  1. ★This thread
  2. 1Clinical Development of AKP-009 for Benign Prostatic Hyperplasia2×
  3. 2Launch of the Dysmenorrhea Treatment DroEthi2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Financial results presentation of 2026-08-04: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.